Moleculin Biotech CS (MBRX) Stock Price, Quote & News

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology

Sector: Healthcare

Phone: (713) 300-5160

Website: moleculin.com

Address:

5300 Memorial Drive, Suite 950, Houston, United States

Zdxss1 Sep. 13 at 12:31 AM

$MBRX Small biotech companies cannot complete Phase III alone because they are unable to do so. They must enter into partnerships, mergers, or acquisitions. This is the challenge. The obstacle to good clinical results is the small number of patients. I believe enrolling 20 patients in Phase III and combining the results with Phase II provides greater confidence and credibility.

1 · Reply

BeauRegard Sep. 13 at 12:17 AM

$MBRX I'd say it's moving sideways after trend break and on the back side of a double bottom. But idk I just work here.

0 · Reply

123rickiek Sep. 13 at 12:09 AM

$MBRX

0 · Reply

123rickiek Sep. 13 at 12:06 AM

$MBRX Well they haven’t been bought and Phase 2 is complete So its gonna be a while before fda approval in my opinion. They will need way more money to bring to market and they still have to reach $1 for compliance.

0 · Reply

Zdxss1 Sep. 12 at 11:55 PM

$MBRX No one waits for the end of the third phase; rather, we await its results, as they determine the fate and future of the company. Technical analysis, indicators, and stock movement are all tricks used by investment funds and hedge funds to dispose of or accumulate shares.

0 · Reply

123rickiek Sep. 12 at 10:40 PM

$MBRX The only good short term news is the warrants. The buyers want to get paid, so they will pump it as the always do and get paid and thats the time to get out if you bought today like i did!!!! If you dont you may go down with the ship for a year or two until phrase 3 is almost done. But there may be another reverse split incurred , just saying !!

0 · Reply

Blocktatch Sep. 12 at 10:37 PM

$MBRX If the good news about the trial comes but it does not explode, I do not know what i will do...

0 · Reply

123rickiek Sep. 12 at 10:35 PM

$MBRX The trend line has not been broken??? Its still on a downward trend!!!!

0 · Reply

Zdxss1 Sep. 12 at 8:10 PM

$MBRX Every Friday, Mr. Waly surprises us with sad news like his face. We hope he changes and brings us happy news.

2 · Reply

BeauRegard Sep. 12 at 6:50 PM

$MBRX I like this. 1yr trend broke about a month ago. Phase 3 info. Took a starter.

0 · Reply

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 8, 2025, 8:30 AM EDT - 6 days ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Aug 28, 2025, 8:30 AM EDT - 17 days ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 27, 2025, 8:45 AM EDT - 18 days ago

Moleculin Issues New Positive AML Overall Survival Data:

Aug 14, 2025, 9:15 AM EDT - 4 weeks ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 8:05 AM EDT - 4 weeks ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 6, 2025, 8:40 AM EDT - 5 weeks ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Jul 30, 2025, 8:35 AM EDT - 6 weeks ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 22, 2025, 8:45 AM EDT - 7 weeks ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 17, 2025, 8:25 AM EDT - 2 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 9, 2025, 8:35 AM EDT - 2 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jun 20, 2025, 9:20 AM EDT - 3 months ago

Moleculin Announces $5.9 Million Public Offering

Jun 18, 2025, 7:45 AM EDT - 3 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:30 AM EDT - 3 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 5, 2025, 8:00 AM EDT - 3 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 3 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

May 14, 2025, 12:20 PM EDT - 4 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 4 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:40 AM EDT - 4 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 7, 2025, 9:00 AM EDT - 4 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 6, 2025, 9:00 AM EDT - 4 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 5, 2025, 8:45 AM EDT - 4 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Apr 29, 2025, 8:35 AM EDT - 4 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 17, 2025, 8:30 AM EDT - 5 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 1, 2025, 8:30 AM EDT - 5 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Mar 24, 2025, 10:50 AM EDT - 6 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 7:05 AM EDT - 6 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 8:05 AM EDT - 6 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 11, 2025, 8:45 AM EDT - 6 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 10, 2025, 8:45 AM EDT - 6 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Mar 6, 2025, 8:30 AM EST - 6 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 3, 2025, 8:30 AM EST - 6 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Feb 25, 2025, 12:35 PM EST - 7 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 13, 2025, 1:19 PM EST - 7 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:05 PM EST - 7 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 9:25 AM EST - 7 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 11, 2025, 8:40 AM EST - 7 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Jan 27, 2025, 8:30 AM EST - 8 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 8, 2025, 8:30 AM EST - 8 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Dec 11, 2024, 8:00 AM EST - 9 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Nov 18, 2024, 8:15 AM EST - 10 months ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 14, 2024, 8:15 AM EST - 10 months ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 12, 2024, 8:00 AM EST - 10 months ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 11, 2024, 11:17 AM EST - 10 months ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 7:05 AM EST - 10 months ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 9:00 AM EST - 11 months ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Nov 4, 2024, 8:30 AM EST - 11 months ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Oct 17, 2024, 8:40 AM EDT - 11 months ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Moleculin to Present at Two Upcoming Investor Conferences

Zdxss1 Sep. 13 at 12:31 AM

1 · Reply

BeauRegard Sep. 13 at 12:17 AM

$MBRX I'd say it's moving sideways after trend break and on the back side of a double bottom. But idk I just work here.

0 · Reply

123rickiek Sep. 13 at 12:09 AM

$MBRX

0 · Reply

123rickiek Sep. 13 at 12:06 AM

0 · Reply

Zdxss1 Sep. 12 at 11:55 PM

0 · Reply

123rickiek Sep. 12 at 10:40 PM

0 · Reply

Blocktatch Sep. 12 at 10:37 PM

$MBRX If the good news about the trial comes but it does not explode, I do not know what i will do...

0 · Reply

123rickiek Sep. 12 at 10:35 PM

$MBRX The trend line has not been broken??? Its still on a downward trend!!!!

0 · Reply

Zdxss1 Sep. 12 at 8:10 PM

$MBRX Every Friday, Mr. Waly surprises us with sad news like his face. We hope he changes and brings us happy news.

2 · Reply

BeauRegard Sep. 12 at 6:50 PM

$MBRX I like this. 1yr trend broke about a month ago. Phase 3 info. Took a starter.

0 · Reply

Papmanny Sep. 12 at 6:43 PM

$MBRX

0 · Reply

jkgyuool Sep. 12 at 5:53 PM

$MBRX many of you all on here for sure scammers. Don’t the rest of you see this manipulation on SP and volume?? All a joke

1 · Reply

Togdjclecj Sep. 12 at 4:28 PM

$MBRX Alright lets do this. I'm in.

0 · Reply

Perpar Sep. 12 at 2:05 PM

$MBRX 🔥🚀

1 · Reply

JIM237 Sep. 12 at 10:41 AM

$MBRX no

0 · Reply

johndoe40 Sep. 12 at 3:34 AM

$MBRX It most certainly will after next R/S.

1 · Reply

Ewolf17 Sep. 12 at 12:45 AM

$MBRX This all you need to know!! If you are serious here,This could 10 x in the coming weeks

0 · Reply

johndoe40 Sep. 11 at 11:56 PM

$MBRX new name same scam,,

0 · Reply

CrisMars Sep. 11 at 10:26 PM

$MBRX I suspect the first deal will be a JV between Moleculin and a first-line cancer drug company. They will form NewCo. Why? It's not simply about the patents; it's about access to the clinicals and know-how. The info is trade secrets and worth a fortune. In a JV setting, both companies work toward a first-line drug, which is a slam dunk if the drug works, and it does. We know that already. This will leave the penny space and never return.

0 · Reply

CrisMars Sep. 11 at 10:14 PM

$MBRX The data unblinding is Q4 of this year. We already know the data will be fantastic from the phase 2 look-see and having proven their drug is the safest-a true noncardiotoxic chemo drug. Also, their new deal guy has yet to post a win, but he will. Great data and news on the way. A stock like this is rare. People aren't posting because we know it's a strong buy.

0 · Reply

TRDKNG Sep. 11 at 9:40 PM

$MBRX the pumpers and pipe dreamers are awfully quiet! 🤔 reality setting in? Lmao

0 · Reply

lexlut Sep. 11 at 6:29 PM

$CMPX $MBRX $OCGN

0 · Reply

Market Cap	13.37M
Revenue (ttm)	0.00
Net Income (ttm)	-21.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,548,700
Avg Vol	6,314,724
Day's Range	N/A - N/A
Shares Out	36.74M
Stochastic %K	22%
Beta	1.50
Analysts	Strong Sell
Price Target	$6.67